Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASCINIT: Safety and Efficacy of Denifanstat in MASH/MASLD
NCT06692283Phase 3Withdrawn
- Sponsor
- Sagimet Biosciences
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of denifanstat in metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Sagimet Biosciences. Planned start Mar 2025; status: withdrawn.
02
Drugs
denifanstat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06692283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692283.